Table of Contents

1 Study Coverage

• 1.1 Pasireotide Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Pasireotide Market Size Growth Rate by Product
  • 1.4.2 0.3mg/ml
  • 1.4.3 0.6mg/ml
  • 1.4.4 0.9mg/ml
• 1.5 Market by End User
  • 1.5.1 Global Pasireotide Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Pharmacy
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Pasireotide Market Size
  • 2.1.1 Global Pasireotide Revenue 2014-2025
  • 2.1.2 Global Pasireotide Sales 2014-2025
• 2.2 Pasireotide Growth Rate by Regions
  • 2.2.1 Global Pasireotide Sales by Regions
  • 2.2.2 Global Pasireotide Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Pasireotide Sales by Manufacturers
  • 3.1.1 Pasireotide Sales by Manufacturers
  • 3.1.2 Pasireotide Sales Market Share by Manufacturers
  • 3.1.3 Global Pasireotide Market Concentration Ratio (CR5 and HHI)
• 3.2 Pasireotide Revenue by Manufacturers
  • 3.2.1 Pasireotide Revenue by Manufacturers (2014-2019)
  • 3.2.2 Pasireotide Revenue Share by Manufacturers (2014-2019)
• 3.3 Pasireotide Price by Manufacturers
• 3.4 Pasireotide Manufacturing Base Distribution, Product Types
  • 3.4.1 Pasireotide Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Pasireotide Product Type
  • 3.4.3 Date of International Manufacturers Enter into Pasireotide Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Pasireotide Sales by Product
• 4.2 Global Pasireotide Revenue by Product
• 4.3 Pasireotide Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Pasireotide Breakdown Data by End User

6 North America

• 6.1 North America Pasireotide by Countries
  • 6.1.1 North America Pasireotide Sales by Countries
  • 6.1.2 North America Pasireotide Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Pasireotide by Product
• 6.3 North America Pasireotide by End User

7 Europe

• 7.1 Europe Pasireotide by Countries
  • 7.1.1 Europe Pasireotide Sales by Countries
  • 7.1.2 Europe Pasireotide Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Pasireotide by Product
• 7.3 Europe Pasireotide by End User

8 Asia Pacific

• 8.1 Asia Pacific Pasireotide by Countries
  • 8.1.1 Asia Pacific Pasireotide Sales by Countries
  • 8.1.2 Asia Pacific Pasireotide Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Pasireotide by Product
• 8.3 Asia Pacific Pasireotide by End User

9 Central & South America

• 9.1 Central & South America Pasireotide by Countries
  • 9.1.1 Central & South America Pasireotide Sales by Countries
  • 9.1.2 Central & South America Pasireotide Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Pasireotide by Product
• 9.3 Central & South America Pasireotide by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Pasireotide by Countries
  • 10.1.1 Middle East and Africa Pasireotide Sales by Countries
  • 10.1.2 Middle East and Africa Pasireotide Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Pasireotide by Product
• 10.3 Middle East and Africa Pasireotide by End User

11 Company Profiles

• 11.1 Novartis
  • 11.1.1 Novartis Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Novartis Pasireotide Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Novartis Pasireotide Products Offered
  • 11.1.5 Novartis Recent Development

12 Future Forecast

• 12.1 Pasireotide Market Forecast by Regions
  • 12.1.1 Global Pasireotide Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Pasireotide Revenue Forecast by Regions 2019-2025
• 12.2 Pasireotide Market Forecast by Product
  • 12.2.1 Global Pasireotide Sales Forecast by Product 2019-2025
  • 12.2.2 Global Pasireotide Revenue Forecast by Product 2019-2025
• 12.3 Pasireotide Market Forecast by End User
• 12.4 North America Pasireotide Forecast
• 12.5 Europe Pasireotide Forecast
• 12.6 Asia Pacific Pasireotide Forecast
• 12.7 Central & South America Pasireotide Forecast
• 12.8 Middle East and Africa Pasireotide Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Pasireotide Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Pasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.
The global Pasireotide market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pasireotide market based on company, product type, end user and key regions.

This report studies the global market size of Pasireotide in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pasireotide in these regions.
This research report categorizes the global Pasireotide market by top players/brands, region, type and end user. This report also studies the global Pasireotide market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis

Market size by Product
0.3mg/ml
0.6mg/ml
0.9mg/ml
Market size by End User
Hospital
Pharmacy

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Pasireotide market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pasireotide market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pasireotide companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pasireotide submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Pasireotide are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pasireotide market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.